The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,004
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.013 · Cited by 82
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 85
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 87
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
Cesaro, A., Schiavo, A., Moscarella, E., Coletta, S., Conte, M., Gragnano, F., Fimiani, F., Monda, E., Caiazza, M., Limongelli, G., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001077 · Cited by 84
Evolving targets for the treatment of atherosclerosis
Solanki, A., Bhatt, L. K., & Johnston, T. P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.002 · Cited by 83
Progress and perspectives in plant sterol and plant stanol research
Jones, P. J. H., Shamloo, M., MacKay, D., Rideout, T. C., Myrie, S. B., Plat, J., Roullet, J., Baer, D. J., Calkins, K. L., Davis, H. R., et al. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy032 · Cited by 86
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 87
Human Genetics of Obesity and Type 2 Diabetes Mellitus
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 86
Duell, P. B., Gidding, S. S., Andersen, R. L., Knickelbine, T., Anderson, L., Gianos, E., Shrader, P. J., Kindt, I., O'Brien, E. C., McCann, D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.007 · Cited by 81
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Brouwers, M. C. G. J., Jacobs, C., Bast, A., Stehouwer, C. D. A., & Schaper, N. C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.004 · Cited by 80
Ferri, N., & Ruscica, M. (2016) · Endocrine · doi:10.1007/s12020-016-0939-0 · Cited by 81
Arrieta, A., Page, T. F., Veledar, E., & Nasir, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169761 · Cited by 78
Schreiber, S. L. (2018) · Israel Journal of Chemistry · doi:10.1002/ijch.201800113 · Cited by 78
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Lee, J. S., Mukhopadhyay, P., Mátyás, C., Trojnár, E., Pálóczi, J., Yang, Y. R., Blank, B. A., Savage, C. H., Sorokin, A. V., Mehta, N. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53603-6 · Cited by 79
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 87
Quantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic Resonance T2 Mapping
Chai, J. T., Biasiolli, L., Li, L., Alkhalil, M., Galassi, F., Darby, C., Halliday, A. W., Hands, L. J., Magee, T. R., Perkins, J. M., et al. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.06.013 · Cited by 76
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell, J. C., Malik, R., Valdés‐Márquez, E., Worrall, B. B., & Collins, R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx373 · Cited by 77
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Luquero, A., Badimón, L., & Borrell-Pagés, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639727 · Cited by 77
Khan, A. R., Bavishi, C., Riaz, H., Farid, T., Khan, S., Atlas, M., Hirsch, G. A., Ikram, S., & Bolli, R. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003153 · Cited by 72
Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis
Ou, L.-C., Zhong, S., Ou, J., & Tian, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0436-0 · Cited by 72
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75
Visconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 75
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 71
Role of PCSK9 in lipid metabolism and atherosclerosis
Lin, X., Xiao, L., Tang, Z., Jiang, Z., & Liu, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.024 · Cited by 78
Xie, W., Liu, J., Wang, W., Wang, M., Qi, Y., Zhao, F., Sun, J., Liu, J., Li, Y., & Zhao, D. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.103 · Cited by 73
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 74
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Low-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis
Zhou, Z., Liang, Y., Zhang, X., Xu, J., Lin, J., Zhang, R., Kang, K., Liu, C., Zhao, C., & Zhao, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00005 · Cited by 73
PCSK9 signaling pathways and their potential importance in clinical practice
Wiciński, M., Żak, J., Malinowski, B., Popek, G., & Grześk, G. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0106-6 · Cited by 74
Current and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 69
The relationship between Lp(a) and CVD outcomes: a systematic review
Forbes, C. A., Quek, R. G. W., Deshpande, S., Worthy, G., Wolff, R. F., Stirk, L., Kleijnen, J., Gandra, S. R., Djedjos, S., & Wong, N. D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0258-8 · Cited by 69
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Ballantyne, C. M., Gellis, L., Tardif, J.-C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., et al. (2026) · JAMA · doi:10.1001/jama.2025.20620 · Cited by 68
Self-citationNonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 69
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70
Intensive LDL-cholesterol lowering therapy and neurocognitive function
Banach, M., Rizzo, M., Nikolić, D., Howard, G., Howard, V. J., & Mikhailidis (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.001 · Cited by 68
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 70
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 67
Swiger, K. J., & Martin, S. S. (2015) · Drug Safety · doi:10.1007/s40264-015-0296-6 · Cited by 65
Microvesicles in Autoimmune Diseases
Liu, M., Williams, K. J., & Werth, V. P. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.06.005 · Cited by 68
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Momtazi‐Borojeni, A. A., Jaafari, M. R., Badiee, A., & Sahebkar, A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.001 · Cited by 68
The Labor Market for Health Workers in Africa
Soucat, A. L. B., & Scheffler, R. M. (2013) · World Bank, Washington, DC eBooks · doi:10.1596/978-0-8213-9555-4 · Cited by 70
PCSK9 inhibitors and cardiovascular disease
Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 66
Feng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Mosley, J. D., Leon, D. A. C., Jiang, L., Ihegword, A., Shaffer, C. M., Linton, M. F., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7223 · Cited by 61
Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes
Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., Feldreich, T., Sundström, J., Carrero, J. J., Leppert, J., Hedberg, P., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4641-z · Cited by 65
Robinson, J. G., & Stone, N. J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv182 · Cited by 65
Self-citationGiugliano, R. P., Mach, F., Zavitz, K. H., Kurtz, C. E., Schneider, J., Wang, H., KEECH, A. C., Pedersen, T. R., Sabatine, M. S., Sever, P. S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22678 · Cited by 64
Self-citationVlachopoulos, C. V., Terentes-Printzios, D. G., Georgiopoulos, G. A., Skoumas, I., Koutagiar, I. P., Ioakeimidis, N., Stefanadis, C., & Tousoulis, D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.922 · Cited by 67
PCSK9 and diabetes: is there a link?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.006 · Cited by 65
Self-citationGenetic-Driven Druggable Target Identification and Validation
Floris, M., Olla, S., Schlessinger, D., & Cucca, F. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.004 · Cited by 67
Statin Treatment in Patients With Intracerebral Hemorrhage
Endres, M., Nolte, C. H., & Scheitz, J. F. (2017) · Stroke · doi:10.1161/strokeaha.117.019322 · Cited by 66
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Self-citationRidker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Nissen, S. E., Revkin, J. H., Santos, R. D., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.010 · Cited by 62
Recent Update on siRNA Therapeutics
Ebenezer, O., Oyebamiji, A. K., Olanlokun, J. O., Tuszyński, J. A., & Wong, G. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083456 · Cited by 71
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 65
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 65
Effects of immunization against PCSK9 in an experimental model of breast cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84734 · Cited by 63
Pećin, I., Hartgers, M. L., Hovingh, G. K., Dent, R. E., & Reiner, Ž. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717346 · Cited by 64
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Ikeda, Y., Wu, D., Hanson, M. E., Hannachi, H., Singhal, P. K., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22583 · Cited by 62
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Chan, D. C., Pang, J., McQuillan, B., Hung, J., Beilby, J. P., Barrett, P. H. R., & Watts, G. F. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.10.017 · Cited by 62
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 60
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 67
Ferri, N., Corsini, A., Macchi, C., Magni, P., & Ruscica, M. (2015) · Translational research · doi:10.1016/j.trsl.2015.10.004 · Cited by 63
PCSK9 inhibitors in clinical practice: Delivering on the promise?
Stoekenbroek, R. M., Hartgers, M. L., Rutte, R., de Wijer, D. D., Stroes, E. S. G., & Hovingh, G. K. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.11.027 · Cited by 60
Extracellular vesicle signalling in atherosclerosis
Charla, E., Mercer, J. R., Maffia, P., & Nicklin, S. A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109751 · Cited by 63
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Understanding PCSK9 and anti-PCSK9 therapies
McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.001 · Cited by 62
Bruckert, É., Parhofer, K. G., González‐Juanatey, J. R., Nordestgaard, B. G., Arca, M., Giovas, P. P., & Ray, K. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01285-2 · Cited by 59
Zeitlinger, M. A., Bauer, M., Reindl‐Schwaighofer, R., Stoekenbroek, R. M., Lambert, G. C., Berger–Sieczkowski, E., Lagler, H., Oesterreicher, Z. A., Wulkersdorfer, B., Lührs, P., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03149-2 · Cited by 59
Grześk, G., Dorota, B., Wołowiec, Ł., Wołowiec, A., Osiak, J., Kozakiewicz, M., & Banach, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113957 · Cited by 64
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 59
New Drugs for Treating Dyslipidemia: Beyond Statins
Ahn, C. H., & Choi, S. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.2.87 · Cited by 58
Ouweneel, A. B., & Eck, M. V. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.10.009 · Cited by 60
Statin Intolerance: the Clinician’s Perspective
Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 59
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59
Precision medicine, genomics and drug discovery: Table 1.
Cardon, L. R., & Harris, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw246 · Cited by 58
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 59
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess, G. P., Natarajan, P., Faridi, K. F., Fievitz, A., Valsdottir, L. R., & Yeh, R. W. (2017) · Circulation · doi:10.1161/circulationaha.117.028430 · Cited by 58
Coronary artery disease in the absence of traditional risk factors: a call for action
Avis, S., Vernon, S. T., Hagström, E., & Figtree, G. A. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab474 · Cited by 57
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 49
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57
Robinson, J. G., Jayanna, M. B., Brown, A. S., Aspry, K. E., Orringer, C. E., Gill, E. A., Goldberg, A. C., Jones, L. K., Maki, K. C., Dixon, D. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.005 · Cited by 57
Self-citationWang, X., & Musunuru, K. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.008 · Cited by 56
Nelson, C. P., Lai, F. Y., Nath, M., Ye, S., Webb, T. R., Schunkert, H., & Samani, N. J. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002196 · Cited by 55
Akbari, P., Sosina, O. A., Bovijn, J., Landheer, K., Nielsen, J. B., Kim, M., Aykul, S., De, T., Haas, M. E., Hindy, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32398-7 · Cited by 58
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 61
Klug, E., Raal, F. J., Marais, A., Smuts, C. M., Schamroth, C., Jankelow, D., Blom, D. J., & Webb, D. A. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i11.13383 · Cited by 56
Self-citationTreatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 58
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Mancina, R. M., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Fracanzani, A. L., et al. (2020) · Liver International · doi:10.1111/liv.14711 · Cited by 54
Momtazi‐Borojeni, A. A., Jaafari, M. R., Afshar, M., Banach, M., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/133885 · Cited by 54
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Wong, N. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100336 · Cited by 54
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
